LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Abierto

1.33 3.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.26

Máximo

1.34

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+55.04% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-24M 78M
Apertura anterior	-1.77
Cierre anterior	1.33

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 mar 2026, 23:01 UTC

Ganancias

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5 mar 2026, 21:54 UTC

Ganancias

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5 mar 2026, 21:35 UTC

Principales Movimientos del Mercado

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5 mar 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5 mar 2026, 23:27 UTC

Charlas de Mercado

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5 mar 2026, 22:54 UTC

Charlas de Mercado

Ganancias

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5 mar 2026, 22:50 UTC

Charlas de Mercado

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5 mar 2026, 22:48 UTC

Ganancias

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5 mar 2026, 22:46 UTC

Ganancias

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5 mar 2026, 22:44 UTC

Ganancias

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 mar 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 mar 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 mar 2026, 21:35 UTC

Ganancias

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:32 UTC

Ganancias

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:26 UTC

Ganancias

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5 mar 2026, 21:24 UTC

Ganancias

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5 mar 2026, 21:23 UTC

Ganancias

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5 mar 2026, 21:22 UTC

Ganancias

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:21 UTC

Ganancias

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5 mar 2026, 21:21 UTC

Ganancias

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5 mar 2026, 21:20 UTC

Ganancias

Costco February Net Sales Were $21.69 B >COST

5 mar 2026, 21:20 UTC

Ganancias

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:20 UTC

Ganancias

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:19 UTC

Ganancias

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5 mar 2026, 21:18 UTC

Ganancias

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5 mar 2026, 21:18 UTC

Ganancias

Costco 2Q Same-Store Sales Up 7.4% >COST

5 mar 2026, 21:15 UTC

Ganancias

Costco 2Q EPS $4.58 >COST

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

55.04% repunte

Estimación a 12 Meses

Media 2 USD 55.04%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.